drugset / Trial / NCT05386524
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer
Timeline
- Start
- 2022-06-15
- Primary completion
- 2025-03-15
- Completion
- 2025-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab Biosimilar | Unknown | 15 mg/kg | Intravenous |
| Subject | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |